Monopar Therapeutics (MNPR) Assets Average (2018 - 2020)

Monopar Therapeutics' Assets Average history spans 3 years, with the latest figure at $15.5 million for Q3 2020.

  • For Q3 2020, Assets Average rose 189.23% year-over-year to $15.5 million; the TTM value through Sep 2020 reached $15.5 million, up 189.23%, while the annual FY2019 figure was $10.3 million, 19.83% up from the prior year.
  • Assets Average for Q3 2020 was $15.5 million at Monopar Therapeutics, up from $12.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $15.5 million in Q3 2020 and bottomed at $5.4 million in Q3 2019.
  • The 3-year median for Assets Average is $8.8 million (2018), against an average of $9.4 million.
  • The largest annual shift saw Assets Average crashed 34.47% in 2019 before it surged 189.23% in 2020.
  • A 3-year view of Assets Average shows it stood at $7.6 million in 2018, then increased by 21.41% to $9.2 million in 2019, then surged by 67.7% to $15.5 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Assets Average are $15.5 million (Q3 2020), $12.8 million (Q2 2020), and $13.1 million (Q1 2020).